Rinvoq has been approved by the European Union to treat rheumatoid arthritis

AbbVie announced that the European Commission (EC) had approved Rinvoq's listing of some patients with moderate to severely active rheumatoid arthritis.
The company disclosed that the once-a-day selectible reversible JAK inhibitor is suitable for patients who do not respond adequately or to the same way to regulating rheumatoids for one or more diseases and can be used as a monotherapy or in combination with methotrexate (MTX).
The decision was based on the results of a phase III selection study in which the treatment met all major and sequential secondary endpoints, indicating that the remission rate was significantly higher than in the placebo and large areas of the Humira (Adamo monoanti) group.
In addition, patients treated with Rinvoq alone received more relief than those treated with MTX.
Professor Andrew Cope, director of the Rheumatology Centre at King's College London, said the results of the studies meant that patients with active diseases had another treatment option with acceptable safety, which could lead to disease relief even if they did not respond adequately to drugs such as methotrexate or anti-tumor necrotizing factors. "
he continued, "Upadacitinib can be used as a single drug, thus benefiting many patients who cannot stand alternative therapies."
Earlier this year, the drug was licensed by the U.S. Food and Drug Administration (FDA) to treat adult patients with moderate to severe active rheumatoid arthritis who do not respond adequately or to the MTX.
Currently, an estimated 400,000 people in the UK suffer from rheumatoid arthritis, most of whom are not in remission. （cyy123.com）